234 related articles for article (PubMed ID: 29035277)
21. Activity of dasatinib against L576P KIT mutant melanoma: molecular, cellular, and clinical correlates.
Woodman SE; Trent JC; Stemke-Hale K; Lazar AJ; Pricl S; Pavan GM; Fermeglia M; Gopal YN; Yang D; Podoloff DA; Ivan D; Kim KB; Papadopoulos N; Hwu P; Mills GB; Davies MA
Mol Cancer Ther; 2009 Aug; 8(8):2079-85. PubMed ID: 19671763
[TBL] [Abstract][Full Text] [Related]
22. Anthelmintic drug niclosamide enhances the sensitivity of chronic myeloid leukemia cells to dasatinib through inhibiting Erk/Mnk1/eIF4E pathway.
Liu Z; Li Y; Lv C; Wang L; Song H
Biochem Biophys Res Commun; 2016 Sep; 478(2):893-9. PubMed ID: 27520370
[TBL] [Abstract][Full Text] [Related]
23. Ribavirin Inhibits the Activity of mTOR/eIF4E, ERK/Mnk1/eIF4E Signaling Pathway and Synergizes with Tyrosine Kinase Inhibitor Imatinib to Impair Bcr-Abl Mediated Proliferation and Apoptosis in Ph+ Leukemia.
Shi F; Len Y; Gong Y; Shi R; Yang X; Naren D; Yan T
PLoS One; 2015; 10(8):e0136746. PubMed ID: 26317515
[TBL] [Abstract][Full Text] [Related]
24. Mitogen-activated Protein Kinase (MAPK) Interacting Kinases 1 and 2 (MNK1 and MNK2) as Targets for Cancer Therapy: Recent Progress in the Development of MNK Inhibitors.
Dreas A; Mikulski M; Milik M; Fabritius CH; Brzózka K; Rzymski T
Curr Med Chem; 2017; 24(28):3025-3053. PubMed ID: 28164761
[TBL] [Abstract][Full Text] [Related]
25. Mitogen-activated protein kinases activate the serine/threonine kinases Mnk1 and Mnk2.
Waskiewicz AJ; Flynn A; Proud CG; Cooper JA
EMBO J; 1997 Apr; 16(8):1909-20. PubMed ID: 9155017
[TBL] [Abstract][Full Text] [Related]
26. Repurposing Ponatinib as a Potent Agent against
Han Y; Gu Z; Wu J; Huang X; Zhou R; Shi C; Tao W; Wang L; Wang Y; Zhou G; Li J; Zhang Z; Sun S
Theranostics; 2019; 9(7):1952-1964. PubMed ID: 31037149
[No Abstract] [Full Text] [Related]
27. Design, synthesis and biological evaluation of 4-aniline-thieno[2,3-d]pyrimidine derivatives as MNK1 inhibitors against renal cell carcinoma and nasopharyngeal carcinoma.
Zhang M; Jiang L; Tao J; Pan Z; He M; Su D; He G; Jiang Q
Bioorg Med Chem; 2019 Jun; 27(11):2268-2279. PubMed ID: 31014565
[TBL] [Abstract][Full Text] [Related]
28. KIT and Melanoma: Biological Insights and Clinical Implications.
Pham DDM; Guhan S; Tsao H
Yonsei Med J; 2020 Jul; 61(7):562-571. PubMed ID: 32608199
[TBL] [Abstract][Full Text] [Related]
29. Update on the Development of MNK Inhibitors as Therapeutic Agents.
Xu W; Kannan S; Verma CS; Nacro K
J Med Chem; 2022 Jan; 65(2):983-1007. PubMed ID: 34533957
[TBL] [Abstract][Full Text] [Related]
30. Spectrum of activity of dasatinib against mutant KIT kinases associated with drug-sensitive and drug-resistant gastrointestinal stromal tumors.
Zeng C; Zhu L; Jia X; Pang Y; Li Z; Lu X; Xie F; Duan L; Wang Y
Gastric Cancer; 2020 Sep; 23(5):837-847. PubMed ID: 32291709
[TBL] [Abstract][Full Text] [Related]
31. MNK1 inhibitor CGP57380 overcomes mTOR inhibitor-induced activation of eIF4E: the mechanism of synergic killing of human T-ALL cells.
Huang XB; Yang CM; Han QM; Ye XJ; Lei W; Qian WB
Acta Pharmacol Sin; 2018 Dec; 39(12):1894-1901. PubMed ID: 30297804
[TBL] [Abstract][Full Text] [Related]
32. Phosphorylation of the cap-binding protein eukaryotic translation initiation factor 4E by protein kinase Mnk1 in vivo.
Waskiewicz AJ; Johnson JC; Penn B; Mahalingam M; Kimball SR; Cooper JA
Mol Cell Biol; 1999 Mar; 19(3):1871-80. PubMed ID: 10022874
[TBL] [Abstract][Full Text] [Related]
33. Mnk1 is required for angiotensin II-induced protein synthesis in vascular smooth muscle cells.
Ishida M; Ishida T; Nakashima H; Miho N; Miyagawa K; Chayama K; Oshima T; Kambe M; Yoshizumi M
Circ Res; 2003 Dec; 93(12):1218-24. PubMed ID: 14605021
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of MNK pathways enhances cancer cell response to chemotherapy with temozolomide and targeted radionuclide therapy.
Grzmil M; Seebacher J; Hess D; Behe M; Schibli R; Moncayo G; Frank S; Hemmings BA
Cell Signal; 2016 Sep; 28(9):1412-1421. PubMed ID: 27289018
[TBL] [Abstract][Full Text] [Related]
35. MNK1 and EIF4E are downstream effectors of MEKs in the regulation of the nuclear export of HDM2 mRNA.
Phillips A; Blaydes JP
Oncogene; 2008 Mar; 27(11):1645-9. PubMed ID: 17828301
[TBL] [Abstract][Full Text] [Related]
36. Human eukaryotic translation initiation factor 4G (eIF4G) recruits mnk1 to phosphorylate eIF4E.
Pyronnet S; Imataka H; Gingras AC; Fukunaga R; Hunter T; Sonenberg N
EMBO J; 1999 Jan; 18(1):270-9. PubMed ID: 9878069
[TBL] [Abstract][Full Text] [Related]
37. STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer Network.
Delyon J; Chevret S; Jouary T; Dalac S; Dalle S; Guillot B; Arnault JP; Avril MF; Bedane C; Bens G; Pham-Ledard A; Mansard S; Grange F; Machet L; Meyer N; Legoupil D; Saiag P; Idir Z; Renault V; Deleuze JF; Hindie E; Battistella M; Dumaz N; Mourah S; Lebbe C;
J Invest Dermatol; 2018 Jan; 138(1):58-67. PubMed ID: 28843487
[TBL] [Abstract][Full Text] [Related]
38. Inhibiting the MNK1/2-eIF4E axis impairs melanoma phenotype switching and potentiates antitumor immune responses.
Huang F; Gonçalves C; Bartish M; Rémy-Sarrazin J; Issa ME; Cordeiro B; Guo Q; Emond A; Attias M; Yang W; Plourde D; Su J; Gimeno MG; Zhan Y; Galán A; Rzymski T; Mazan M; Masiejczyk M; Faber J; Khoury E; Benoit A; Gagnon N; Dankort D; Journe F; Ghanem GE; Krawczyk CM; Saragovi HU; Piccirillo CA; Sonenberg N; Topisirovic I; Rudd CE; Miller WH; Del Rincón SV
J Clin Invest; 2021 Apr; 131(8):. PubMed ID: 33690225
[TBL] [Abstract][Full Text] [Related]
39. Optimization of 4,6-Disubstituted Pyrido[3,2-
Han Y; Zhang H; Wang S; Li B; Xing K; Shi Y; Cao H; Zhang J; Tong T; Zang J; Guan L; Gao X; Wang Y; Liu D; Huang M; Jing Y; Zhao L
J Med Chem; 2021 Sep; 64(18):13719-13735. PubMed ID: 34515481
[TBL] [Abstract][Full Text] [Related]
40. KIT as a therapeutic target in metastatic melanoma.
Carvajal RD; Antonescu CR; Wolchok JD; Chapman PB; Roman RA; Teitcher J; Panageas KS; Busam KJ; Chmielowski B; Lutzky J; Pavlick AC; Fusco A; Cane L; Takebe N; Vemula S; Bouvier N; Bastian BC; Schwartz GK
JAMA; 2011 Jun; 305(22):2327-34. PubMed ID: 21642685
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
